Clinical trial
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand…
NCT00458679 · Baylor College of Medicine, Other · Completed
Key facts
| NCT number | NCT00458679 |
|---|---|
| Title | Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells |
| Official title | Prolonged Immunization With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells for Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) |
| Acronym | PRIMAL |
| Lead sponsor | Baylor College of Medicine, Other |
| Collaborators | The Methodist Hospital Research Institute Center for Cell and Gene Therapy, Baylor College of Medicine |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia (CLL) |
| Intervention type | Biological |
| Interventions | CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE |
| Enrollment | 6 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Aug 1, 2013 |
| First posted | Apr 11, 2007 |
| Last update posted | Feb 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: